Peter Hardin, MD
Radiation Oncology · Campbellsville, KYNPI 1366419814
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 149 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 9.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $798 and has fallen 77.7% since, to $178 in 2024.
Across 149 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$248
- Merck$239
- Amgen$201
- Incyte Corporation$189
- AstraZeneca$185
- Seagen Inc.$150
- plus $1K from 34 others
What the payments were for
- Food & beverage$2,59998%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 15 | $248 |
| Merck | 16 | $239 |
| Amgen | 9 | $201 |
| Incyte Corporation | 10 | $189 |
| AstraZeneca(2 entities) | 10 | $185 |
| Seagen Inc. | 10 | $150 |
| Sanofi | 8 | $135 |
| Bristol Myers Squibb | 5 | $85 |
| Lilly USA, LLC | 5 | $84 |
| Novartis | 4 | $77 |
| Genentech USA, Inc. | 3 | $60 |
| Rigel Pharmaceuticals, Inc. | 2 | $59 |
| Puma Biotechnology, Inc. | 4 | $58 |
| Bayer | 4 | $58 |
| Tesaro, Inc. | 3 | $53 |
| G1 Therapeutics, Inc. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $51 |
| GSK | 2 | $47 |
| AMAG Pharmaceuticals, Inc. | 3 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| Karyopharm Therapeutics Inc. | 2 | $40 |
| Accuray Incorporated | 1 | $40 |
| ADC Therapeutics America, Inc. | 2 | $39 |
| Stemline Therapeutics Inc. | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $36 |
| Foundation Medicine, Inc. | 2 | $35 |
| AbbVie | 2 | $34 |
| Pfizer | 2 | $32 |
| Tersera Therapeutics LLC | 1 | $25 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $25 |
| Verastem, Inc. | 1 | $25 |
| Coherus Oncology, Inc. | 1 | $23 |
| Genmab U.S., Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Blueprint Medicines Corporation | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Novocure Inc. | 1 | $15 |
| Brainlab, Inc. | 1 | $10 |
How this compares
$2,645 in reported general payments places this provider in the 80th percentile of 81 radiation oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Campbellsville
- Neal DunlapLouisville$98K
- Elyn WangPikeville$21K
- Eddy YangLexington$20K
- Craig SilvermanLouisville$9K
- Shiao WooLouisville$7K
- Ryan AbelOwensboro$6K
- Brian WilliamsLexington$5K
- Justin AndersonLouisville$5K
- Aaron SpaldingLouisville$5K
- Yong ChaLouisville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.